

Special Issue

Osteosarcoma: From Pathophysiology to Novel Therapeutic Approaches

Message from the Guest Editor

Osteosarcoma (OS) is the most common primitive bone tumor in children and adolescents, with a second peak incidence in older adulthood. Although treatment with surgery and multiagent intensive chemotherapy results in a 60–70% rate of long-term disease-free survival for localized patients, the chance of curing the disease dramatically drops for metastatic patients and patients with chemoresistant tumors. The identification of novel therapeutic approaches is challenging due to the rarity of the disease and osteosarcoma's biological features, such as tumor heterogeneity, complex karyotypes, and genomic instability. This Special Issue will present a collection of original research articles and reviews highlighting osteosarcoma's pathophysiologic mechanisms, including epigenetic and metabolic regulation, angiogenesis, microenvironment, and immune system interactions, and will help to address advances in new therapeutic strategies.

Guest Editor

Dr. Elisabetta Setola

Divisione di Oncologia Medica del Melanoma e Sarcomi, Melanoma and Sarcoma Medical Treatment, IEO—European Institute of Oncology, 435-20141 Milan, Italy

Deadline for manuscript submissions

closed (31 July 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/122102

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).